Valproic Acid for the Prevention of Post-Amputation Pain

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Duke University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT01928849
First received: February 15, 2013
Last updated: June 13, 2014
Last verified: June 2014
  Purpose

The objectives of this study are, to test the effectiveness of Valproic Acid (VPA) in the prevention of chronic neuropathic and post-amputation pain, as well as to further define the underlying inflammatory and epigenetic mechanisms that lead to the development of such chronic pain.

HYPOTHESES AND QUESTIONS

Hypothesis 1: The use of oral valproic acid in combination with regional anesthesia in surgical limb-injury patients will decrease the incidence of chronic nerve injury and post-amputation pain.

Goal 1: In a blinded, randomized placebo-controlled, multi-center clinical trial, investigators will determine if oral VPA added to regional anesthesia and standard perioperative management will reduce the incidence of nerve injury and post-amputation pain when compared with regional anesthesia alone.

Hypothesis 2: The transition from acute to chronic pain is mediated via epigenetic mechanisms (differential DNA methylation) in genes involved in nociception.

Goal 2: Investigators will analyze the DNA methylation patterns of patients with different types of neuropathic and post-amputation pain and determine if they are altered by VPA.


Condition Intervention Phase
Pain, Phantom
Pain, Neuropathic
Drug: Valproic Acid
Other: Cherry Syrup
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Efficacy of Valproic Acid in reducing the Incidence of chronic neuropathic and post-amputation pain. [ Time Frame: 3 month assessment ] [ Designated as safety issue: Yes ]
    The primary endpoint is the incidence of chronic pain 3 months after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain.


Secondary Outcome Measures:
  • Neuropathic limb or post-amputation pain, and the incidence of pain sub-types [ Time Frame: Assessments at enrollment, during hospitalization, as well as 1, 3 and 6 months post-surgery ] [ Designated as safety issue: No ]
    The incidence of neuropathic limb or post-amputation pain sub-types at the time points of 1, 3, and 6 months after surgery.

  • Effect on analgesic requirement [ Time Frame: Assessments at enrollment, during hospitalization, as well as 1, 3 and 6 months post-surgery ] [ Designated as safety issue: Yes ]
    The effect of study drug on perioperative analgesic use and corresponding analysis of pain/sedation scales.

  • Qualitative characterization of pain sub-types [ Time Frame: Assessment at 3 months post-surgery ] [ Designated as safety issue: No ]
    Qualitative characterization of neuropathic limb and post-amputation pain sub-types.


Other Outcome Measures:
  • Observation of epigenetic alterations that occur in the transition from acute to chronic pain. [ Time Frame: 3 months through to end of study, approximately 4 years ] [ Designated as safety issue: No ]
    Epigenetic analysis (DNA methylation) will be correlated with pain sub-type and use of Valproic Acid.


Estimated Enrollment: 420
Study Start Date: December 2013
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Cherry syrup
Cherry Syrup: Patients randomized to the "Control arm" of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Other: Cherry Syrup
Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
Experimental: Valproic Acid
"Intervention arm" patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Drug: Valproic Acid
"Intervention" patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.
Other Name: Depacon, Depakene, Depakote, Stavzor

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female active duty military personnel or veterans, age 18 years and older.
  • Patient is scheduled to undergo amputation, stump revision, or surgery for a limb injury with neurologic damage.
  • Patient able to provide written informed consent prior to any study procedures.

Exclusion Criteria:

  • Severe Traumatic Brain Injury (Diagnosis of traumatic brain injury resulting in documented, permanent or prolonged cognitive deficits that would preclude participation in the study)
  • Significant cognitive deficits or dementia of any cause as noted in Computerized Patient Record System(CPRS).
  • Patient has a designated Legally Authorized Representative
  • Substantial hearing loss without alternative means of communication.
  • Patient has documented spinal cord injury with permanent or persistent deficits
  • Patient is under age 18 or a legal Minor
  • Current pregnancy or lactation
  • Cirrhosis with evidence of decompensation: coagulopathy International Normalized Ratio (INR) >1.3, thrombocytopenia with platelets <100,000, ascites or hepatic encephalopathy
  • Current therapy with valproic acid or other valproates, coumadin, chlorpromazine and olanzapine
  • Current diagnosis of seizure disorder requiring anti-epileptic medication
  • Current therapy with tricyclic antidepressants (eg: amitriptyline, nortriptyline, imipramine, desipramine) at doses greater than 50mg/day
  • Currently taking zidovudine
  • Current diagnosis of malaria requiring anti-malaria medication (such as mefloquine and chloroquine)
  • Currently taking monoamine oxide inhibitors (MAOI)
  • Allergy to valproates or valproic acid
  • End-stage renal disease requiring dialysis
  • Contraindication to, or refusal of, regional anesthesia catheter
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01928849

Contacts
Contact: Dionne R Apedjihoun, MS 919-286-0411 ext 7372
Contact: Mary M Kirkley 919-681-0711 mary.kirkley@dm.duke.edu

Locations
United States, Maryland
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20814
Contact: Mary McDuffie, RN    301-816-4722    mmcduffie@dvpmi.org   
Principal Investigator: Chester T Buckenmaier III, MD         
Sub-Investigator: Lisa L Bleckner, MD         
United States, North Carolina
Duham VA Medical Center Recruiting
Durham, North Carolina, United States, 27705
Contact: Dionne R Apedjihoun, MS    919-286-0411 ext 7372    dionne.apedjihoun@dm.duke.edu   
Contact: Mary M Kirkley    919-681-1170    Mary.kirkley@duke.edu   
Principal Investigator: Thomas E Buchheit, MD         
Sub-Investigator: Andrew D Shaw, MD         
Sub-Investigator: Thomas Van de Ven, MD         
Sub-Investigator: Juliann Hobbs, MD         
Sub-Investigator: Karthik Raghunathan, MD         
Sub-Investigator: Srinivas Pyati, MD         
Sub-Investigator: Cynthia K Shortell, MD         
Sponsors and Collaborators
Duke University
Investigators
Principal Investigator: Thomas E Buchheit, MD Duke University
  More Information

Publications:
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01928849     History of Changes
Other Study ID Numbers: Pro00047194, PT110575
Study First Received: February 15, 2013
Last Updated: June 13, 2014
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Duke University:
Amputation
Post-amputation Pain
Neuropathic pain
Valproic Acid
Anesthesia, Conduction
Neuralgia, stump

Additional relevant MeSH terms:
Phantom Limb
Neuralgia
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Perceptual Disorders
Neurobehavioral Manifestations
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Anesthetics
Valproic Acid
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Antimanic Agents
Tranquilizing Agents
Psychotropic Drugs

ClinicalTrials.gov processed this record on August 27, 2014